During the corresponding time, Twist Bioscience Corporation recorded a revenue increase by 23.24 % year on year, sequentially revenue grew by 6.92 %. While revenue at the Twist Bioscience Corporation's corporate clients
Twist Bioscience's Comment on Sales, Marketing and Customers
Twist Bioscience provides products to customers in healthcare, food and agriculture, industrial chemicals and materials, and academic research. Their offerings support applications including antibody discovery and optimization in healthcare; sustainable production of specialty chemicals and materials such as spider silk and nylon; sustainable crop production in food and agriculture; and various educational and research activities in academia. In fiscal year 2025, the company served over 3,800 customers worldwide and generated $376.6 million in revenue, with $215.1 million from healthcare, $93.2 million from chemicals and materials, $65.9 million from academic research, and $2.4 million from food and agriculture. Twist Bioscience’s synthetic biology and next-generation sequencing tools are utilized in drug discovery, disease detection, and enzyme engineering.
Twist Bioscience: Leading the Charge in Biotechnological Innovation at the Upcoming J.P. Morgan Healthcare Conference South San Francisco, CA As the landscape of the life sciences sector continues to evolve, Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in synthetic DNA technology, is set to further solidify its position at the 43rd Annual J.P. Morgan Healthcare Conference. CEO and co-founder Emily M. Leproust, Ph.D. will take center stage on January 13, 2025, at 5:15 p.m. Pacific Time, presenting groundbreaking advancements in biotechnology that are shaping the future of healthcare. The J.P. Morgan Healthcare Conference has long been regarded as a premier platform for companies to showca...
Advances in Synthetic Biology: Twist Bioscience s New Launches in Viral Controls and High-Throughput ScreeningTwist Bioscience Corporation (NASDAQ: TWST), a company renowned for its innovations in synthetic DNA using its proprietary silicon platform, has recently announced two significant advancements designed to meet the growing demands in viral research and high-throughput screening. Synthetic RNA Control for H5N1 Influenza AIn a move aimed at enhancing scientific research and control efforts related to the H5N1 Influenza A virus, Twist Bioscience has unveiled a synthetic RNA control that covers 99.9% of hemagglutinin (HA) and neuraminidase (NA) genes. H5N1 is one of the viruses causing Highly Pathogenic ...
Twist Bioscience Joins AI Safety Consortium: A Leap Towards Trustworthy Biosecurity In an era where artificial intelligence (AI) and biotechnology are rapidly converging, ensuring the safety and trustworthiness of these technologies is paramount. Twist Bioscience Corporation, a leading company known for its high-quality synthetic DNA offerings, has made a strategic move by joining the U.S. AI Safety Institute Consortium (AISIC). This consortium, established by the Department of Commerce s National Institute of Standards and Technology (NIST), aims to support the development and deployment of safe and reliable AI systems. Participation in AISIC: A Strategic Move Twist Bioscience’s participation in the AISI...
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome SequencingSOUTH SAN FRANCISCO, Calif. - Twist Bioscience Corporation (NASDAQ: TWST), a leading company in synthetic DNA production using its silicon platform, announced the launch of its Twist Precision Dx next-generation sequencing (NGS) products that comply with the European Union (EU) in vitro diagnostic regulations (IVDR). These products are designed to provide accurate and reliable results for whole exome sequencing, an important tool in genomic research and precision medicine.The EU has implemented IVDR regulations to ensure the safety, performance, and quality of in vitro diagnostic medical devices, which includes NGS produ...
Twist Bioscience Corporation, the renowned provider of high-quality synthetic DNA solutions using its state-of-the-art silicon platform, has announced the expansion of its revolutionary gene synthesis service, Twist Express Genes. The service, originally introduced in November 2023, offers customers the unique advantage of a swift order-to-shipping turnaround, starting at just five business days. In an exciting development, Twist Bioscience is now extending the capabilities of Express Genes to include larger DNA preparations, scaling up to 1 milligram.With the rapid advancement of genetic engineering and synthetic biology, the demand for high-quality DNA synthesis services has been on the rise. Twist Bioscie...
Twist Bioscience’s Comment on Sales, Marketing and Customers
Twist Bioscience provides products to customers in healthcare, food and agriculture, industrial chemicals and materials, and academic research. Their offerings support applications including antibody discovery and optimization in healthcare; sustainable production of specialty chemicals and materials such as spider silk and nylon; sustainable crop production in food and agriculture; and various educational and research activities in academia. In fiscal year 2025, the company served over 3,800 customers worldwide and generated $376.6 million in revenue, with $215.1 million from healthcare, $93.2 million from chemicals and materials, $65.9 million from academic research, and $2.4 million from food and agriculture. Twist Bioscience’s synthetic biology and next-generation sequencing tools are utilized in drug discovery, disease detection, and enzyme engineering.
Sources:
Twist Bioscience Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Twist Bioscience Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Twist Bioscience Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
168.91 %